Scinai Immunotherapeutics
SCNI
11 hedge funds and large institutions have $2.51M invested in Scinai Immunotherapeutics in 2018 Q3 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
8% less funds holding
Funds holding: 12 → 11 (-1)
16% less capital invested
Capital invested by funds: $2.98M → $2.51M (-$468K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VIA
Vantage Investment Advisors
State College,
Pennsylvania
|
+$23.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$19.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$23.9K |
| 2 |
BHB
Bank Hapoalim BM
Tel Aviv,
Israel
|
-$10.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
II
1
Ibex Investors
Denver,
Colorado
| $2.01M | – | – | – |
|
|
BHB
2
Bank Hapoalim BM
Tel Aviv,
Israel
| $141K | -$10.1K | -17 | -6% |
|
|
VIA
3
Vantage Investment Advisors
State College,
Pennsylvania
| $140K | +$23.9K | +40 | +19% |
|
4
HighTower Advisors
Chicago,
Illinois
| $94K | – | – | – |
|
|
PVH
5
Psagot Value Holdings
Tel Aviv,
Israel
| $61K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $25K | +$19.7K | +33 | +254% |
|
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $15K | -$23.9K | -40 | -61% |
|
|
LTFS
8
Ladenburg Thalmann Financial Services
Miami,
Florida
| $14K | – | – | – |
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $5K | – | – | – |
|
11
Morgan Stanley
New York
| $3K | – | – | – |
|
SCNI Hedge Fund Activity: Q3 2018 in Review
11 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2018, worth a combined $2.51M — down 16% from $2.98M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of SCNI and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Vantage Investment Advisors, adding an estimated $23.9K. The largest seller was Deutsche Bank, cutting an estimated $23.9K.
- 11 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2018, down from 12 in Q2 2018.
- Funds reported $2.51M of Scinai Immunotherapeutics stock for Q3 2018, down 16% quarter-over-quarter.
- 0 funds opened new Scinai Immunotherapeutics positions in Q3 2018 and 1 closed out, a net change of -1 holder.
- The largest Scinai Immunotherapeutics buyer in Q3 2018 was Vantage Investment Advisors, an estimated $23.9K added.
- The largest Scinai Immunotherapeutics seller in Q3 2018 was Deutsche Bank, an estimated $23.9K sold.
Based on aggregated 13F filings for Q3 2018.